Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 2 (1)
P 4 (1)

Trial Status

Not Yet Recruiting1
Completed1
Enrolling By Invitation1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07369622Phase 4Not Yet RecruitingPrimary

HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness

NCT06971146Not ApplicableRecruiting

Nurse-Led Telehealth for Gout

NCT06822933Not ApplicableEnrolling By InvitationPrimary

The Remote Monitoring of Gout Study

NCT05936281Phase 2Completed

A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)

Showing all 4 trials

Research Network

Activity Timeline